Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Small Vessel VCID Biomarker Validation Consortium Sites (U01)(Clinical Trials Not Allowed)
T?o invite applications to an open competition to be one of up to 7 supported sites in the next phase of the NINDS small vessel vascular contributions to cognitive impairment and dementia (VCID) biomarkers consortium.
The original consortium, established under RFA-NS-16-019 and RFA-NS-16-020,
pursued initial stages of multi-site validation of 11 candidate imaging-based and fluid-based biomarkers.
The primary objective of the next 5 years is to carry out comprehensive multi-site clinical validation of up to six of these 11 biomarkers to be selected by the NINDS in a process separate from this FOA.
The focus will be validation in longitudinal studies of diverse all-comers populations that are typical in clinical settings in the United States.
The network of sites will provide scientific expertise and experimental infrastructure to pursue these goals synergistically including with the Coordinating Center (RFA-NS-21-004).
At the conclusion of clinical validation each biomarker will have a designated category and context of use as defined by the FDA and a finalized public protocol that describes all details needed to utilize the biomarker.
The sites will drive the consortium scientifically and contribute administratively to comprehensive rigorous clinical validation of biomarkers for future clinical trials, including in large phase III trials, and for generating scientific breakthroughs in our understanding and treatment of VCID.
The original consortium, established under RFA-NS-16-019 and RFA-NS-16-020,
pursued initial stages of multi-site validation of 11 candidate imaging-based and fluid-based biomarkers.
The primary objective of the next 5 years is to carry out comprehensive multi-site clinical validation of up to six of these 11 biomarkers to be selected by the NINDS in a process separate from this FOA.
The focus will be validation in longitudinal studies of diverse all-comers populations that are typical in clinical settings in the United States.
The network of sites will provide scientific expertise and experimental infrastructure to pursue these goals synergistically including with the Coordinating Center (RFA-NS-21-004).
At the conclusion of clinical validation each biomarker will have a designated category and context of use as defined by the FDA and a finalized public protocol that describes all details needed to utilize the biomarker.
The sites will drive the consortium scientifically and contribute administratively to comprehensive rigorous clinical validation of biomarkers for future clinical trials, including in large phase III trials, and for generating scientific breakthroughs in our understanding and treatment of VCID.
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $8,400,000
Office: National Institutes of Health
Estimated Funding: $8,400,000
Who's Eligible
Obtain Full Opportunity Text:
http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-005.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U. S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U. S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-005.html
Contact:
Agency Email Description:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Agency Email:
Date Posted:
2020-11-23
Application Due Date:
Archive Date:
2021-04-14
Follow @topgovtgrant
Social Entrepreneurship
Spotlight
Is Corporate Philanthropy Dead?
Senay Ataselim-Yilmaz, Chief Operating Officer, Turkish Philanthropy Funds, writes that philanthropy often solves the very problems that stems from market failure. Some social issues, however, Â cannot be tackled by questioning the return on investment.
Nonprofit Jobs in Alabama
Fundraising & Development Jobs
Social Services Employment
Substance Abuse Jobs
Program Director Jobs
Social Services Jobs
Learn How to Identify and Avoid Grant Scams
